Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

36 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Secukinumab Exhibits Sustained and Stable Response in Patients with Moderate-to-Severe Psoriasis: Results from the SUPREME Study.
Costanzo A, Russo F, Galluzzo M, Stingeni L, Scuderi R, Zichichi L, Papini M, Di Costanzo L, Conti A, Burlando M, Chiricozzi A, Gaiani FM, Mugheddu C, Musumeci ML, Gisondi P, Piaserico S, Dapavo P, Venturini M, Pagnanelli G, Amerio P, Potenza C, Peris K, Cantoresi F, Trevisini S, Loconsole F, Offidani A, Mercuri SR, Lora V, Prignano F, Bartezaghi M, Oliva G, Aloisi E, Orsenigo R. Costanzo A, et al. Among authors: orsenigo r. Acta Derm Venereol. 2021 Oct 21;101(10):adv00576. doi: 10.2340/00015555-3816. Acta Derm Venereol. 2021. PMID: 33903916 Free PMC article. Clinical Trial.
Effectiveness of cyclosporine A in patients with moderate to severe plaque psoriasis in a real-life clinical setting in Italy: the TRANSITION study.
Marsili F, Travaglini M, Stinco G, Manzoni R, Tiberio R, Prignano F, Mazzotta A, Cannavò SP, Cuccia A, Germino M, Bongiorno MR, Persechino S, Florio T, Pettinato M, Tabanelli M, Sarkar R, Aloisi E, Bartezaghi M, Orsenigo R. Marsili F, et al. Among authors: orsenigo r. J Dermatolog Treat. 2022 Feb;33(1):401-407. doi: 10.1080/09546634.2020.1757017. Epub 2020 Apr 30. J Dermatolog Treat. 2022. PMID: 32349568
Secukinumab Use in Patients with Moderate to Severe Psoriasis, Psoriatic Arthritis and Ankylosing Spondylitis in Real-World Setting in Europe: Baseline Data from SERENA Study.
Kiltz U, Sfikakis PP, Gaffney K, Sator PG, von Kiedrowski R, Bounas A, Gullick N, Conrad C, Rigopoulos D, Lespessailles E, Romanelli M, Ghislain PD, Brandt-Jürgens J, Rashkov R, Aassi M, Orsenigo R, Perella C, Pournara E, Gathmann S, Jagiello P, Veit J, Augustin M. Kiltz U, et al. Among authors: orsenigo r. Adv Ther. 2020 Jun;37(6):2865-2883. doi: 10.1007/s12325-020-01352-8. Epub 2020 May 6. Adv Ther. 2020. PMID: 32378070 Free PMC article.
Secukinumab treatment leads to normalization of quality of life and disease symptoms in psoriasis patients with or without prior systemic psoriasis therapy: the PROSE study results.
Augustin M, Dauden E, Mrowietz U, Konstantinou MP, Gerdes S, Kingo K, Szepietowski JC, Perrot JL, Cuccia A, Rissler M, Gathmann S, Sieder C, Orsenigo R, Jagiello P, Bachhuber T. Augustin M, et al. Among authors: orsenigo r. J Eur Acad Dermatol Venereol. 2021 Feb;35(2):431-440. doi: 10.1111/jdv.16632. Epub 2020 Jul 1. J Eur Acad Dermatol Venereol. 2021. PMID: 32426889
Secukinumab Improves Patient Perception of Anxiety and Depression in Patients with Moderate to Severe Psoriasis: A Post hoc Analysis of the SUPREME Study.
Talamonti M, Malara G, Natalini Y, Bardazzi F, Conti A, Chiricozzi A, Mugheddu C, Gisondi P, Piaserico S, Pagnanelli G, Amerio P, Potenza C, Cantoresi F, Fargnoli MC, Balato A, Loconsole F, Offidani A, Bonifati C, Prignano F, Bartezaghi M, Rausa A, Aloisi E, Orsenigo R, Costanzo A; the SUPREME Study Group. Talamonti M, et al. Among authors: orsenigo r. Acta Derm Venereol. 2021 Mar 31;101(3):adv00422. doi: 10.2340/00015555-3712. Acta Derm Venereol. 2021. PMID: 33269404 Free PMC article. Clinical Trial.
Baseline characteristics of patients with moderate-to-severe psoriasis according to previous systemic treatment exposure: the PROSE study population.
Augustin M, Dauden E, Mrowietz U, Konstantinou MP, Gerdes S, Rissler M, Gathmann S, Sieder C, Baeumer D, Orsenigo R. Augustin M, et al. Among authors: orsenigo r. J Eur Acad Dermatol Venereol. 2020 Nov;34(11):2548-2556. doi: 10.1111/jdv.16400. Epub 2020 May 20. J Eur Acad Dermatol Venereol. 2020. PMID: 32239541
Alisporivir with peginterferon/ribavirin in patients with chronic hepatitis C genotype 1 infection who failed to respond to or relapsed after prior interferon-based therapy: FUNDAMENTAL, a Phase II trial.
Buti M, Flisiak R, Kao JH, Chuang WL, Streinu-Cercel A, Tabak F, Calistru P, Goeser T, Rasenack J, Horban A, Davis GL, Alberti A, Mazzella G, Pol S, Orsenigo R, Brass C. Buti M, et al. Among authors: orsenigo r. J Viral Hepat. 2015 Jul;22(7):596-606. doi: 10.1111/jvh.12360. Epub 2014 Nov 21. J Viral Hepat. 2015. PMID: 25412795 Clinical Trial.
36 results